MJFF awards Nine Square Therapeutics $4.5m for Parkinson’s disease research
15 Sep 2023
Preview
Source: PMLiVE
The Michael J Fox Foundation (MJFF) has awarded Nine Square Therapeutics a research grant totalling $4.5m to accelerate the development of novel Parkin activators for the treatment of Parkinson’s disease (PD).
Nine Square, a biotechnology company discovering novel small molecules to treat severe neurodegenerative diseases, said that the grant will contribute to accelerating the identification of drug candidates and could potentially deliver significant benefits to people living with PD.
Globally, PD is the fastest-growing neurological disease and currently affects more than 10 million people worldwide.
As a challenging condition to diagnose, varying symptoms and early signs of the condition such as tremors, stiffness and slowness, are primarily relied on in order to diagnose patients. However, symptoms often appear many years after the onset of PD.
Mutations in Parkin, an intracellular protein that regulates mitochondrial quality control by selectively promoting the degradation of dysfunctional mitochondria, are strongly associated with early-onset PD.
Nine Square has developed small-molecule candidates to promote Parkin activity to clear dysfunctional mitochondria and protect dopaminergic neurons.
"Our Parkin activators have demonstrated the ability to promote mitochondrial turnover and improve mitochondrial function in cellular models of Parkinson’s disease," said Tina Schwabe, vice president and head of biology at Nine Square Therapeutics.
She added: "We look forward to using these funds to advance the nomination of our clinical candidate."
Commenting on the grant, Jessica Garcia, associate director of research programmes at MJFF, said that the foundation is “pleased to support researchers at emerging companies like Nine Square that have a differentiated approach to drug and target discovery and are committed to ushering in a brighter future for patients around the globe".
In April this year, a study led by the MJFF identified a breakthrough biomarker that can reveal the key pathology of PD.
Based on the study results, researchers say that they can confirm and measure the presence of the Parkinson’s protein, alpha-synuclein protein, to determine the likelihood of someone developing the disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.